Marcia Irene Canto

Marcia Irene Canto

Auto-generated profile, based on publicly available information

Marcia Irene Canto

Johns Hopkins University 9 Department of Medicine, The Sol Goldman Pancreatic Cancer Research Center Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2012 in Gut
Verified
Journal Article
Open access
PDF file
MCMarcia Irene Canto
Marcia Irene Canto
FHFemme Harinck
Femme Harinck
RHRalph H Hruban
Ralph H Hruban
GOGeorge Johan Offerhaus
George Johan Offerhaus
JPJan-Werner Poley
Jan-Werner Poley
MBMarco Bruno
Marco Bruno
Background: Screening individuals at increased risk for pancreatic cancer (PC) detects early, potentially curable, pancreatic neoplasia. Objective: To develop consortium statements on screening, surveillance and management of high-risk individuals with an inherited predisposition to PC. Methods: A 49-expert multidisciplinary international consortium met to discuss pancreatic screening and vote on statements. Consensus was considered reached if ≥75% agreed or disagreed. Results: There was excellent agreement that, to be successful, a screening programme should detect and treat T1N0M0 margin-negative PC and high-grade dysplastic precursor lesions (pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasm). It was agreed that the following were candidates for screening: first-degree relatives (FDRs) of patients with PC from a familial PC kindred with at least two affected FDRs; patients with Peutz–Jeghers syndrome; and p16 , BRCA 2 and hereditary non-polyposis colorectal cancer (HNPCC) mutation carriers with ≥1 affected FDR. Consensus was not reached for the age to initiate screening or stop surveillance. It was agreed that initial screening should include endoscopic ultrasonography (EUS) and/or MRI/magnetic resonance cholangiopancreatography not CT or endoscopic retrograde cholangiopancreatography. There was no consensus on the need for EUS fine-needle aspiration to evaluate cysts. There was disagreement on optimal screening modalities and intervals for follow-up imaging. When surgery is recommended it should be performed at a high-volume centre. There was great disagreement as to which screening abnormalities were of sufficient concern to for surgery to be recommended. Conclusions: Screening is recommended for high-risk individuals, but more evidence is needed, particularly for how to manage patients with detected lesions. Screening and subsequent management should take place at high-volume centres with multidisciplinary teams, preferably within research protocols.

1 April 2012 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
MCMarcia Irene Canto
Marcia Irene Canto
RHRalph H. Hruban
Ralph H. Hruban
EFEliot Keith Fishman
Eliot Keith Fishman
IKIhab R. Kamel
Ihab R. Kamel
RSRichard Schulick
Richard Schulick
MGMichael Goggins
Michael Goggins

1 June 2006 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
MCMarcia Irene Canto
Marcia Irene Canto
MGMichael Goggins
Michael Goggins
RHRalph H. Hruban
Ralph H. Hruban
GPGloria M. Petersen
Gloria M. Petersen
FGFrancis M. Giardiello
Francis M. Giardiello
AKAnthony N. Kalloo
Anthony N. Kalloo

1 September 2018 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
MCMarcia Irene Canto
Marcia Irene Canto
JAJose Alejandro Almario
Jose Alejandro Almario
RSRichard D. Schulick
Richard D. Schulick
CYCharles J. Yeo
Charles J. Yeo
AKAlison Klein
Alison Klein
MGMichael Goggins
Michael Goggins

1 July 2004 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
MCMarcia Irene Canto
Marcia Irene Canto
MGMichael Goggins
Michael Goggins
CYCharles J. Yeo
Charles J. Yeo
CGConstance Griffin
Constance Griffin
JAJennifer E. Axilbund
Jennifer E. Axilbund
RHRalph H. Hruban
Ralph H. Hruban

15 June 2022 in Journal of Clinical Oncology
Verified
Journal Article
Open access
MDMohamad Dbouk
Mohamad Dbouk
BKBryson W Katona
Bryson W Katona
RBRandall E. Brand
Randall E. Brand
ACAmitabh Chak
Amitabh Chak
SSSapna Syngal
Sapna Syngal
MGMichael Goggins
Michael Goggins
PURPOSE: To report pancreas surveillance outcomes of high-risk individuals within the multicenter Cancer of Pancreas Screening-5 (CAPS5) study and to update outcomes of patients enrolled in prior CAPS studies. METHODS: Individuals recommended for pancreas surveillance were prospectively enrolled into one of eight CAPS5 study centers between 2014 and 2021. The primary end point was the stage distribution of pancreatic ductal adenocarcinoma (PDAC) detected (stage I v higher-stage). Overall survival was determined using the Kaplan-Meier method. RESULTS: Of 1,461 high-risk individuals enrolled into CAPS5, 48.5% had a pathogenic variant in a PDAC-susceptibility gene. Ten patients were diagnosed with PDAC, one of whom was diagnosed with metastatic PDAC 4 years after dropping out of surveillance. Of the remaining nine, seven (77.8%) had a stage I PDAC (by surgical pathology) detected during surveillance; one had stage II, and one had stage III disease. Seven of these nine patients with PDAC were alive after a median follow-up of 2.6 years. Eight additional patients underwent surgical resection for worrisome lesions; three had high-grade and five had low-grade dysplasia in their resected specimens. In the entire CAPS cohort (CAPS1-5 studies, 1,731 patients), 26 PDAC cases have been diagnosed, 19 within surveillance, 57.9% of whom had stage I and 5.2% had stage IV disease. By contrast, six of the seven PDACs (85.7%) detected outside surveillance were stage IV. Five-year survival to date of the patients with a screen-detected PDAC is 73.3%, and median overall survival is 9.8 years, compared with 1.5 years for patients diagnosed with PDAC outside surveillance (hazard ratio [95% CI]; 0.13 [0.03 to 0.50], P = .003). CONCLUSION: Most pancreatic cancers diagnosed within the CAPS high-risk cohort in the recent years have had stage I disease with long-term survival.